Novartis: Renal Insufficiency, Chronic trials
The registry lists 28 Renal Insufficiency, Chronic studies with Novartis as lead sponsor. 4 are open to participants now and 11 have results posted.
Phase 1 4Phase 2 8Phase 3 12Phase 4 3No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruitingNCT07498335Phase 3
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney DiseaseRecruitingNCT07235059Phase 1
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.RecruitingNCT06858319Phase 3
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyRecruitingNCT04557462Phase 3
- A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRPCompletedNCT06362759Phase 2Results posted
- Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA NephropathyCompletedNCT05834738Phase 2Results posted
- Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell DiseaseCompletedNCT04053764Phase 2Results posted
- Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by InflammationCompletedNCT03373461Phase 2Results posted
- Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal FunctionCompletedNCT02678000Phase 2Results posted
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)CompletedNCT01950819Phase 4Results posted
- Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin AlfaCompletedNCT01693029Phase 3Results posted
- HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)CompletedNCT01576341Phase 3Results posted
- Safety and Tolerability of Valsartan in Children 6 to 17 Years of AgeCompletedNCT01365481Phase 3Results posted
- Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis PatientsTerminatedNCT00701714Phase 3Results posted
- Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.CompletedNCT00632125Phase 4Results posted
- A Study of Zigakibart in Adults With IgA NephropathyActive, not recruitingNCT05852938Phase 3
- Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Phase 3
- An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal DysfunctionCompletedNCT01846468Phase 1
- Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney DiseaseWithdrawnNCT01593527Phase 3
- Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric PatientsCompletedNCT01447485Phase 1
- Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft RejectionCompletedNCT01353417
- MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5CompletedNCT01121237
- Placebo Versus SBR759 in Lowering Phosphate in Dialysis PatientsCompletedNCT01069692Phase 3
- Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)WithdrawnNCT00869856Phase 3
- A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on HemodialysisCompletedNCT00750295Phase 1/2
- Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on HemodialysisCompletedNCT00704678Phase 2
- Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on HemodialysisCompletedNCT00704483Phase 2
- Trial to Evaluate the Efficacy of Fluvastatin on Certain MarkersCompletedNCT00171262Phase 4